Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis

Podobne knjige/članki

• Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women
  od: Nakamura, Yukio, et al.
  Izdano: (2017)
• Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment
  od: Nakamura, Yukio, et al.
  Izdano: (2017)
• Efficacy, safety, and compliance of ibandronate treatment for 3 years in postmenopausal Japanese women with primary osteoporosis
  od: Suzuki, Takako, et al.
  Izdano: (2018)
• Pretreatment of daily teriparatide enhances the increase of bone mineral density in cortical bones by denosumab therapy
  od: Kamimura, Mikio, et al.
  Izdano: (2018)
• Calcium and vitamin D supplementation with 3-year denosumab treatment is beneficial to enhance bone mineral density in postmenopausal patients with osteoporosis and rheumatoid arthritis
  od: Suzuki, Takako, et al.
  Izdano: (2018)